3 Good Stocks Paying Dividends Every August
Whether you’re pulling in a paycheck or living off investments, dividends can be a great way to reel in some cash.
A is for August — and AT&T and AbbVie and Apple, three stocks that pay dividends in August.
Many companies dole out dividends in March, June, September and December. If all your payments land in that timetable, your income stream can dry up for long stretches.
To keep the cash flowing right through vacation, we sorted through payment dates to identify when companies pay out. We focused on firms with steady businesses, sturdy balance sheets and a commitment to uphold their payouts. Check out our August offerings. (Prices and data are as of June 30.)
Sign up for Kiplinger’s Free E-Newsletters
Profit and prosper with the best of expert advice on investing, taxes, retirement, personal finance and more - straight to your e-mail.
Profit and prosper with the best of expert advice - straight to your e-mail.
SEE ALSO: Great Stocks to Get Dividends Every Month
AT&T
Symbol: T
Price: $43
Yield: 4.4%
Annual dividend rate: $1.92
Price-earnings ratio: 15
Also pays in: February, May, November
AT&T’s purchase of DirecTV last year is boosting results. Analysts see the telecom giant’s revenues rising 12%, to $165 billion this year, with profits climbing 5%, to $17.6 billion. Growth of such magnitude isn’t likely to last, but AT&T should still be a solid earner, thanks to new TV services it plans to roll out. To help retain customers, the firm is also offering package deals with unlimited mobile data for subscribers who buy TV service, too. The knock on AT&T is that the stock, selling for about 15 times estimated year-ahead earnings, is pricey relative to its earnings growth. But compared with the paltry yield on Treasuries, the stock’s 4.4% yield looks appealing. AT&T’s dividend should keep rising, though modestly. Analysts see AT&T lifting the payout by 2% next year.
AbbVie
Symbol: ABBV
Price: $66
Yield: 3.4%
Annual dividend rate: $2.28
Price-earnings ratio: 13
Also pays in: February, May, November
AbbVie produces Humira, one of the world’s best-selling drugs. Physicians are prescribing Humira for a growing array of illnesses, including rheumatoid arthritis, Crohn’s disease and psoriasis. Raking in more than $14 billion in annual sales, Humira accounts for more than half of AbbVie revenues and an even higher proportion of the firm’s profits, which are rising steadily.
Unfortunately, Humira’s starring role won’t last. Its U.S. patent expires at the end of 2016. But because Humira is a complex biotech drug, generic versions will likely take several years to gain traction in the marketplace and may not wind up being much less expensive than Humira. Meanwhile, AbbVie is expanding its roster of drugs to treat blood cancers and other diseases. Wall Street sees earnings growth of 12% this year and 18% in 2017.
Apple
Symbol: AAPL
Price: $104
Yield: 2.2%
Annual dividend rate: $2.28
Price-earnings ratio: 12
Also pays in: February, May, November
Skepticism about Apple runs so high that the stock’s price-earnings ratio of 12 is 35% less than the P/E of the average big utility.
Bears argue that Apple’s innovation machine has stalled and that its flagship product, the iPhone, won’t lure as many customers as expected in China and other key markets, where lower-priced smartphones are making inroads. Yet Apple’s competitive strengths remain formidable. Its “ecosystem” of hardware, software and services keeps many customers locked in and coming back for new products. Sales are likely to pick up with the expected September launch of the iPhone 7. Apple is also developing additional revenue streams, such as a new subscription model for app developers and paid search ads on its App Store site. With $233 billion in cash and securities on its balance sheet and access to low-cost debt, Apple’s finances provide plenty of firepower for more dividend hikes.
SEE ALSO: 6 Good Dividend Stocks That Yield 5% or More
Get Kiplinger Today newsletter — free
Profit and prosper with the best of Kiplinger's advice on investing, taxes, retirement, personal finance and much more. Delivered daily. Enter your email in the box and click Sign Me Up.
-
Stock Market Today: The Dow Adds 15 Points To End Its Losing Streak
Equity indexes opened higher but drifted lower as markets priced in new Fed forecasts.
By David Dittman Published
-
What Is a Qualified Charitable Distribution (QCD)?
Tax Breaks A QCD can lower your tax bill while meeting your charitable giving goals in retirement. Here’s how.
By Kate Schubel Published
-
Stock Market Today: Stocks End Mixed Ahead of Powell
Political upheaval in South Korea kept investors on their toes Tuesday.
By Karee Venema Published
-
Why Is Warren Buffett Selling So Much Stock?
Berkshire Hathaway is dumping equities, hoarding cash and making market participants nervous.
By Dan Burrows Published
-
If You'd Put $1,000 Into Google Stock 20 Years Ago, Here's What You'd Have Today
Google parent Alphabet has been a market-beating machine for ages.
By Dan Burrows Published
-
Stock Market Today: Stocks Drop, Oil Spikes After Iran Attacks Israel
A massive port strike and dismal economic data also weighed on the main indexes Tuesday.
By Karee Venema Published
-
Stock Market Today: Stocks Gain After Powell Talks Rate Cuts
A late-day burst of buying power helped the main indexes close higher for the day, month and quarter.
By Karee Venema Published
-
Apple Stock's a Buy Ahead of Apple Event 2024
Apple stock is on Wall Street's radar ahead of the tech giant's annual September product event, which begins on Monday. Here's what analysts are saying and what you can expect to see.
By Joey Solitro Published
-
Stock Market Today: Stocks Retreat Ahead of Nvidia Earnings
Markets lost ground on light volume Wednesday as traders keyed on AI bellwether Nvidia earnings after the close.
By Dan Burrows Published
-
Stock Market Today: Stocks Edge Higher With Nvidia Earnings in Focus
Nvidia stock gained ground ahead of tomorrow's after-the-close earnings event, while Super Micro Computer got hit by a short seller report.
By Karee Venema Published